Medical devices, healthcare technology and the business of care
PMA approval · P250039

LIAISON Biotrin Parvovirus B19 IgM Plus, LIAISON Biotrin Control Parvovirus B19 IgM Plus

DiaSorin, Inc. · Decision date May 7, 2026

FDA DECISIONP250039

What did the FDA approve?

FDA records P250039 as an original PMA application. The recorded decision is approval, dated May 7, 2026.

FDA approval order statement

Approval for LIAISON Biotrin Parvovirus B19 IgM Plus and LIAISON Biotrin Control Parvovirus B19 IgM Plus. The LIAISON Biotrin Parvovirus B19 IgM Plus, a chemiluminescent immunoassay (CLIA), is intended for the qualitative detection of IgM antibodies to human parvovirus B19 in human serum, lithium heparin, K2-EDTA and sodium citrated plasma. This test, in conjunction with the LIAISON Biotrin Parvovirus B19 IgG Plus (chemiluminescent immunoassay), may be used for testing women of childbearing age to determine their serological status where there is a suspicion of exposure to human parvovirus B19. The results of these assays may be used to make a serological determination of past, recent, or current infection with parvovirus B19. The test may also be used for all patients as an aid in the diagnosis of fifth disease (erythema infectiosum). The test must be performed on the LIAISON XL Analyzer.
Regulatory pathway
Original PMA
Clinical specialty
Microbiology
Decision date
May 7, 2026

FDA source record

Regulatory record facts

Identifier
P250039
Regulatory pathway
Premarket approval application
Product code
MYM
Decision code
APPR
Decision date
May 7, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: ASSAY,ENZYME LINKED IMMUNOSORBENT,PARVOVIRUS B19 IGM.

Product code
MYM
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P250039 received

    Application receipt date recorded by FDA.

  2. P250039 · FDA decision

    APPR

  3. P250039/S001 · Related supplement

    LIAISON Biotrin Parvovirus B19 IgM Plus, LIAISON Biotrin Control Parvovirus B19 IgM Plus

Timeline entries are records held by MedtechLedger for P250039. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250039

Product / regulatory recordCompanyPathwayDecision dateSource
DiaSorin, Inc.PMA supplementJun 24, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

DiaSorin, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1951 Northwestern Ave., Stillwater, MN, 55082

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records